CR8398A - Metodos para el tratamiento del asma - Google Patents
Metodos para el tratamiento del asmaInfo
- Publication number
- CR8398A CR8398A CR8398A CR8398A CR8398A CR 8398 A CR8398 A CR 8398A CR 8398 A CR8398 A CR 8398A CR 8398 A CR8398 A CR 8398A CR 8398 A CR8398 A CR 8398A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pkc
- methods
- agents
- protein
- asthma
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a metodos para agentes utiles para tratar asma. Los metodos incluyen seleccionar agentes que inhiben la produccion de una proteina PKC-0, asi como tambien agentes que inhiben la actividad de cinasa de una proteina PKC-0, o un fragmento funcional de la misma, en donde tales agentes son utiles para tratar el asma. Tambien se incluyen metodos para seleccionar agentes que inhiben la produccion de un producto de gen reportero codificado por una secuencia de acido nucleico operablemente ligada a un promotor de PKC-0. Tambien se describen metodos para tratar asma que incluyen, administrar un agente que inhibe la produccion de una proteina de PKC-0 funcional o la actividad de cinasa de una proteina de PKC-0 o un fragmento funcional de la misma. Tambien se describe una celula mastil aislada que carece de la expresion de una PKC-0 endogena.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53252503P | 2003-12-24 | 2003-12-24 | |
US58941504P | 2004-07-20 | 2004-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8398A true CR8398A (es) | 2006-10-06 |
Family
ID=34743021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8398A CR8398A (es) | 2003-12-24 | 2006-05-11 | Metodos para el tratamiento del asma |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050164323A1 (es) |
EP (1) | EP1702214A4 (es) |
JP (1) | JP2007525210A (es) |
KR (1) | KR20060127415A (es) |
AU (1) | AU2004308441A1 (es) |
BR (1) | BRPI0417212A (es) |
CA (1) | CA2545722A1 (es) |
CR (1) | CR8398A (es) |
EC (1) | ECSP066672A (es) |
IL (1) | IL175351A0 (es) |
MX (1) | MXPA06007094A (es) |
NO (1) | NO20062496L (es) |
RU (1) | RU2006126704A (es) |
WO (1) | WO2005062918A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
CA2535029C (en) | 2003-08-07 | 2013-07-16 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
DE102005020754B3 (de) * | 2005-05-02 | 2007-01-11 | Altana Pharma Ag | Zelluläres Assayverfahren zur Identifizierung von PKCtheta-Inhibitoren |
EP2452691A3 (en) * | 2005-08-29 | 2012-09-05 | HealOr Ltd. | Methods and compositions for prevention of diabetic and aged skin |
US7883855B2 (en) * | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
GB0617222D0 (en) * | 2006-08-31 | 2006-10-11 | Vereniging Het Nl Kanker I | Antibiotics |
US7914999B2 (en) * | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
EP2118654B1 (en) * | 2006-12-29 | 2013-03-27 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
EP2118657B1 (en) | 2006-12-29 | 2014-05-21 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
ES2393135T3 (es) | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
US20090155784A1 (en) * | 2007-01-22 | 2009-06-18 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
EP2137215A2 (en) * | 2007-04-23 | 2009-12-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
KR20130121678A (ko) * | 2007-07-30 | 2013-11-06 | 힐로 리미티드 | 약제학적 조성물 및 관련 방법 |
WO2010017473A2 (en) * | 2008-08-07 | 2010-02-11 | The Salk Institute For Biological Studies | Method of identifying ikk2 activators or inhibitors |
ES2635504T3 (es) | 2009-01-21 | 2017-10-04 | Rigel Pharmaceuticals, Inc. | Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas |
WO2011068898A1 (en) | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
EP2595982B1 (en) | 2010-07-21 | 2018-06-13 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
RU2526146C2 (ru) * | 2012-09-27 | 2014-08-20 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ профилактики и лечения бронхиальной астмы, осложняющих ее респираторных вирусных инфекций и других воспалительных заболеваний дыхательных путей |
EP2928891B1 (en) | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
CA2904610A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5574094A (en) * | 1992-11-30 | 1994-06-22 | Biosignal Kutato-Fejleszto Kft. | Polyunsaturated fatty acyl-peptide composition |
US5776716A (en) * | 1994-02-01 | 1998-07-07 | Terrapin Technologies, Inc. | Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof |
US5935803A (en) * | 1994-02-01 | 1999-08-10 | Terrapin Technologies, Inc. | Methods to identify immunomodulators using cognate interaction of PKC-theta |
US6054286A (en) * | 1996-06-18 | 2000-04-25 | Telik, Inc. | Methods to identify immunomodulators using cognate interaction of PKC-theta |
US6040152A (en) * | 1996-12-31 | 2000-03-21 | National Jewish Medical And Research Center | Method and assay for regulation of T cell proliferation |
US6103712A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for asthma |
EP1115847A1 (en) * | 1998-09-25 | 2001-07-18 | Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
WO2000036083A2 (en) * | 1998-12-17 | 2000-06-22 | La Jolla Institute For Allergy And Immunology | Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them |
SE9902387D0 (sv) * | 1999-06-22 | 1999-06-22 | Astra Ab | New pharmaceutically active compounds |
US6190869B1 (en) * | 1999-10-26 | 2001-02-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of protein kinase C-theta expression |
AU2460601A (en) * | 1999-12-27 | 2001-07-09 | La Jolla Institute For Allergy | Methods for identifying agents capable of modulating protein kinase c theta (pkctheta) activity |
-
2004
- 2004-12-22 KR KR1020067012717A patent/KR20060127415A/ko not_active Application Discontinuation
- 2004-12-22 RU RU2006126704/15A patent/RU2006126704A/ru unknown
- 2004-12-22 MX MXPA06007094A patent/MXPA06007094A/es unknown
- 2004-12-22 JP JP2006547362A patent/JP2007525210A/ja not_active Withdrawn
- 2004-12-22 WO PCT/US2004/043281 patent/WO2005062918A2/en active Application Filing
- 2004-12-22 US US11/022,327 patent/US20050164323A1/en not_active Abandoned
- 2004-12-22 CA CA002545722A patent/CA2545722A1/en not_active Abandoned
- 2004-12-22 AU AU2004308441A patent/AU2004308441A1/en not_active Withdrawn
- 2004-12-22 BR BRPI0417212-4A patent/BRPI0417212A/pt not_active IP Right Cessation
- 2004-12-22 EP EP04815366A patent/EP1702214A4/en not_active Withdrawn
-
2006
- 2006-05-01 IL IL175351A patent/IL175351A0/en unknown
- 2006-05-11 CR CR8398A patent/CR8398A/es not_active Application Discontinuation
- 2006-05-31 NO NO20062496A patent/NO20062496L/no not_active Application Discontinuation
- 2006-06-23 EC EC2006006672A patent/ECSP066672A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1702214A2 (en) | 2006-09-20 |
AU2004308441A1 (en) | 2005-07-14 |
WO2005062918A2 (en) | 2005-07-14 |
EP1702214A4 (en) | 2007-12-19 |
KR20060127415A (ko) | 2006-12-12 |
WO2005062918A3 (en) | 2005-08-25 |
ECSP066672A (es) | 2006-10-25 |
NO20062496L (no) | 2006-09-11 |
JP2007525210A (ja) | 2007-09-06 |
MXPA06007094A (es) | 2006-08-23 |
US20050164323A1 (en) | 2005-07-28 |
BRPI0417212A (pt) | 2007-02-06 |
IL175351A0 (en) | 2006-09-05 |
CA2545722A1 (en) | 2005-07-14 |
RU2006126704A (ru) | 2008-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8398A (es) | Metodos para el tratamiento del asma | |
BR112021018303A2 (pt) | Novos inibidores de pequenas moléculas de fatores de transcrição tead | |
MX2020010871A (es) | Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia. | |
CY1117683T1 (el) | Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47 | |
BRPI0507373A (pt) | compostos e método de uso | |
EP3929285A3 (en) | Methods of reducing odor | |
BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
CL2012000583A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras. | |
CL2011001578A1 (es) | Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña. | |
CU24269B1 (es) | 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante | |
AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
CO2022003552A2 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
ATE423134T1 (de) | Verbesserte sezernierung von neublastin | |
ATE440950T1 (de) | Konstrukte und verfahren zur regulation der genexpression | |
NO20053112L (no) | Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike. | |
MX2007006746A (es) | Proceso novedoso para la manufactura de derivados del acido 3-pirrolidin-2-il-propionico. | |
AR101101A1 (es) | Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer | |
UA86399C2 (ru) | Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза | |
PE20210811A1 (es) | Acido ribonucleico bicatenario capaz de suprimir la expresion de c5 de complemento | |
Zhang et al. | A survey of the venom of the spider Lycosa vittata by biochemical, pharmacological and transcriptomic analyses | |
PA8642901A1 (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa i | |
ECSP22008949A (es) | Partículas virales para uso en el tratamiento de sinucleinopatías tal como enfermedad de parkinson mediante terapia génica | |
MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
ATE415416T1 (de) | Methode für die herstellung von protamin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |